Last March 26-29, 2025, the European Lung Cancer Congress (ELCC) 2025 was held in Paris, France. In addition to the new and developing drugs, David Burger presented a poster titled “The Information-seeking Behaviour of Health Care Providers for Drug-Drug Interaction Signals with Lung Cancer Agents“.

Patients with lung cancer face an increased risk of drug-drug interactions (DDIs) due to polypharmacy and novel treatments.

A study using the Lung Cancer DDI Manager analyzed 1310 global queries from Dec 2023 to Dec 2024, assessing interactions between 14 lung cancer drugs and 984 comedications. Results showed that 46% of queries involved clinically relevant interactions, with 8.9% being contraindicated.

Frequently queried drugs included repotrectinib, osimertinib, and paclitaxel, while commonly checked comedications were antithrombotics, antivirals, and urological drugs. The results show that health care providers find a clinically relevant interaction in almost half of all queries.

The data give insights of the global population's commonly used lung cancer drugs and comedications. The information could serve both educational activities on DDIs and prioritize DDI studies with lung cancer agents.